PE20081361A1 - Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas - Google Patents
Composiciones farmaceuticas de clonazepam y metodos de uso de las mismasInfo
- Publication number
- PE20081361A1 PE20081361A1 PE2007001144A PE2007001144A PE20081361A1 PE 20081361 A1 PE20081361 A1 PE 20081361A1 PE 2007001144 A PE2007001144 A PE 2007001144A PE 2007001144 A PE2007001144 A PE 2007001144A PE 20081361 A1 PE20081361 A1 PE 20081361A1
- Authority
- PE
- Peru
- Prior art keywords
- solvent
- clonazepam
- clonazepan
- percentage
- weight
- Prior art date
Links
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical group C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003120 clonazepam Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002904 solvent Substances 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000012062 aqueous buffer Substances 0.000 abstract 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 1
- 235000013773 glyceryl triacetate Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960002622 triacetin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) CLONAZEPAN EN UNA CATIDAD TERAPEUTICA ENTRE 0,1 MG Y 5,0 MG Y PRESENTE EN UN PORCENTAJE EN PESO ENTRE 0,1% Y 20% Y b) UN SISTEMA DE DISOLVENTE QUE CONSTA AL MENOS DE UN PRIMER DISOLVENTE EN EL QUE EL CLONAZEPAN ES SOLUBLE TAL COMO MONOETIL ETER DE DIETILENGLICOL O ETER DE POLIETILEN GLICOL DE ALCOHOL DE TETRAHIDROFURFURILICO PRESENTE EN UN PORCENTAJE EN PESO ENTRE 30% Y 70%; Y UN SEGUNDO DISOLVENTE EN EL QUE EL CLONAZEPAM ES MENOS SOLUBLE QUE CON EL PRIMERO, TAL COMO TRIACETATO DE GLICEROL O PROPILENGLICOL; ADEMAS ESTE SISTEMA COMPRENDE EL 10% O MENOS DE UNA DISOLUCION TAMPON ACUOSA, CON LA SALVEDAD DE QUE EL SISTEMA DE DISOLVENTE NO COMPRENDE POLIMEROS DE POLIETILENGLICOL LIBRES. ESTA COMPOSICION ES DE ADMINISTRACION TRANSMUCOSA O TRANSNASAL, DE CORTA ACCION, SIENDO UTIL PARA EL TRATAMIENTO DE CONVULSIONES REPETIDAS, ATAQUES DE PANICO, ESPASMOS MUSCULARES Y ANSIEDAD
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84056806P | 2006-08-28 | 2006-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081361A1 true PE20081361A1 (es) | 2008-11-06 |
Family
ID=38819711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001144A PE20081361A1 (es) | 2006-08-28 | 2007-08-23 | Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8609651B2 (es) |
| EP (2) | EP2056877A2 (es) |
| JP (2) | JP2010502612A (es) |
| KR (1) | KR20090043603A (es) |
| CN (1) | CN101528261B (es) |
| AR (1) | AR062556A1 (es) |
| AU (1) | AU2007290589B2 (es) |
| BR (1) | BRPI0714907A2 (es) |
| CA (1) | CA2662197A1 (es) |
| IL (1) | IL197275A0 (es) |
| MX (1) | MX2009002310A (es) |
| NO (1) | NO20091211L (es) |
| NZ (2) | NZ595388A (es) |
| PE (1) | PE20081361A1 (es) |
| TW (1) | TW200824693A (es) |
| UY (1) | UY30561A1 (es) |
| WO (2) | WO2008027357A2 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200824693A (en) | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| AU2008206105B2 (en) * | 2007-01-19 | 2014-04-03 | Hananja Ehf | Methods and compositions for the delivery of a therapeutic agent |
| KR20100047311A (ko) | 2007-08-31 | 2010-05-07 | 아르키메데스 디벨로프먼트 리미티드 | 비-수성 약학 조성물 |
| GB0716907D0 (en) * | 2007-08-31 | 2007-10-10 | Archimedes Dev Ltd | Pharmaceutical powder compositions |
| CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| WO2010126970A1 (en) * | 2009-04-28 | 2010-11-04 | Optmed, Inc. | Methods for treating and preventing erectile dysfunction |
| CA2760451A1 (en) * | 2009-04-28 | 2010-11-04 | Optmed, Inc. | Compositions and methods for treating and preventing overactive bladder and conditions associated therewith |
| GB2481407B (en) * | 2010-06-22 | 2012-05-23 | Special Products Ltd | A rapid onset liquid midazolam composition for buccal administration |
| RU2018135967A (ru) * | 2011-03-31 | 2018-11-14 | Акорда Терапьютикс, Инк. | Интраназальные фармацевтические композиции на основе бензодиазепина |
| DK3415139T3 (da) | 2011-06-14 | 2022-06-20 | Neurelis Inc | Administration af benzodiazepin |
| AU2012352528B9 (en) * | 2011-12-11 | 2017-11-02 | Baudax Bio, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
| US9125805B2 (en) * | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
| EP2958594A4 (en) * | 2013-02-22 | 2017-03-01 | Eastgate Pharmaceuticals Inc. | Pharmaceutical composition for enhanced transmucosal administration of benzodiazepines |
| KR101635635B1 (ko) * | 2014-12-04 | 2016-07-01 | 주식회사 엘지생활건강 | 디팔미토일 하이드록시프롤린과 갈릭산 에스터 유도체를 함유하는 화장료 조성물 |
| WO2016191413A1 (en) | 2015-05-25 | 2016-12-01 | Iso Therapeutics Group, Llc | Dotmp kit formulations for radioisotopes |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| KR20190104531A (ko) * | 2016-12-09 | 2019-09-10 | 알렉스자 파마스티칼즈, 인크. | 간질 치료 방법 |
| US20200390754A1 (en) * | 2017-11-17 | 2020-12-17 | Neurana Pharmaceuticals, Inc. | Methods of administering tolperisone |
| EP3735223A4 (en) | 2018-01-05 | 2021-10-13 | Impel Neuropharma Inc. | INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE |
| US10896106B2 (en) | 2018-05-10 | 2021-01-19 | Teradyne, Inc. | Bus synchronization system that aggregates status |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| US20200338090A1 (en) * | 2019-04-29 | 2020-10-29 | Marsh and Wang Medical Systems, LLC | Seizure control compositions and methods of using same |
| CN110420190B (zh) * | 2019-08-29 | 2021-07-09 | 湖南洞庭药业股份有限公司 | 氯硝西泮片及其制备方法 |
| AU2022290861A1 (en) * | 2021-06-10 | 2023-12-07 | Neurelis, Inc. | Methods and compositions for treating seizure disorders in pediatric patients |
| CN115707451A (zh) * | 2021-08-19 | 2023-02-21 | 北京万全德众医药生物技术有限公司 | 氯硝西泮口服溶液 |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| CN118812444A (zh) * | 2022-03-02 | 2024-10-22 | 济南同路医药科技发展有限公司 | 一种喹唑啉类化合物及其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266466A (en) * | 1987-01-14 | 1993-11-30 | President And Fellows Of Harvard College | Method of using T7 DNA polymerase to label the 3' end of a DNA molecule |
| SE8800080L (sv) | 1988-01-13 | 1989-07-14 | Kabivitrum Ab | Laekemedelskomposition |
| US4950664A (en) * | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
| FR2656303B1 (fr) | 1989-12-26 | 1994-06-10 | Parke Davis | Solution buvable d'un derive des benzodiazepines et son application pharmacologique. |
| DK0532546T3 (da) | 1990-05-10 | 1998-12-28 | Nycomed Pharma As | Farmaceutisk præparat indeholdende N-glycofuroler og N-ethylenglycoler |
| DE4021263C2 (de) * | 1990-07-04 | 1996-04-11 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| FR2692174B1 (fr) | 1992-06-16 | 1994-08-19 | Valois | Dispositif à gaz comprimé pour projeter sous forme finement divisée une dose unique d'une substance fluide. |
| DK17093D0 (da) * | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
| WO1995029678A1 (en) | 1994-04-28 | 1995-11-09 | F.Hoffmann-La Roche Ag | Pharmaceutical composition for transdermal delivery |
| GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
| US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
| DE19756442A1 (de) * | 1997-12-18 | 1999-06-24 | Pfeiffer Erich Gmbh & Co Kg | Spender für Medien |
| US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| GB9826192D0 (en) | 1998-12-01 | 1999-01-20 | Controlled Theraputics Scotlan | Oral transmucosal delivery |
| ATE393626T1 (de) * | 1999-07-26 | 2008-05-15 | Sk Holdings Co Ltd | Transnasale anticonvulsive zusammensetzungen |
| DE19938798A1 (de) * | 1999-08-16 | 2001-03-01 | Pfeiffer Erich Gmbh & Co Kg | Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte |
| DE19940236A1 (de) | 1999-08-25 | 2001-03-08 | Pfeiffer Erich Gmbh & Co Kg | Spender mit manuell betätigbarer Ausbringeinrichtung |
| US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| DE60143360D1 (de) | 2000-08-03 | 2010-12-09 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert |
| FR2815611B1 (fr) * | 2000-10-23 | 2003-04-11 | Valois Sa | Tete de distribution et distributeur de produit fluide comportant une telle tete de distribution |
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| US7262185B2 (en) * | 2001-08-08 | 2007-08-28 | Takeda Chemical Industries Ltd. | Benzazepine derivative, process for producing the same, and use |
| CN1642576A (zh) | 2002-02-25 | 2005-07-20 | 药物发展有限公司 | 吸收增强剂 |
| US6742677B2 (en) * | 2002-04-18 | 2004-06-01 | Valois S.A.S. | Fluid dispenser pump |
| AU2003233653B2 (en) * | 2002-05-23 | 2008-08-07 | Umd, Inc. | Compositions and method for transmucosal drug delivery and cryoprotection |
| US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
| ITRM20020357A1 (it) | 2002-07-03 | 2004-01-05 | Foscama Biomed Chim Farma | Composizione liquida per la somministrazione orale di lorazepam. |
| ES2270335T7 (es) | 2003-01-31 | 2012-03-16 | Orexo Ab | Composicion farmaceuta de efecto. |
| JP2006527764A (ja) | 2003-06-17 | 2006-12-07 | エスケー コーポレイション | ジアゼパムを含有する経鼻マイクロエマルジョン |
| MXPA06003316A (es) * | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Formulacion farmaceutica transdermica para minimizar los residuos en la piel. |
| EP1845942B1 (en) | 2005-01-14 | 2014-04-09 | Camurus Ab | Gnrh analogue formulations |
| US20070021411A1 (en) | 2005-05-11 | 2007-01-25 | Cloyd James C | Supersaturated benzodiazepine solutions and their delivery |
| TW200824693A (en) | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| US9319244B2 (en) | 2010-12-22 | 2016-04-19 | Usablenet Inc. | Methods for emailing labels as portable data files and devices thereof |
-
2007
- 2007-08-14 TW TW096130010A patent/TW200824693A/zh unknown
- 2007-08-23 PE PE2007001144A patent/PE20081361A1/es not_active Application Discontinuation
- 2007-08-27 NZ NZ595388A patent/NZ595388A/en not_active IP Right Cessation
- 2007-08-27 CA CA002662197A patent/CA2662197A1/en not_active Abandoned
- 2007-08-27 EP EP07811570A patent/EP2056877A2/en not_active Withdrawn
- 2007-08-27 JP JP2009526675A patent/JP2010502612A/ja not_active Ceased
- 2007-08-27 MX MX2009002310A patent/MX2009002310A/es not_active Application Discontinuation
- 2007-08-27 EP EP07837400A patent/EP2068933A2/en not_active Withdrawn
- 2007-08-27 BR BRPI0714907-7A patent/BRPI0714907A2/pt not_active IP Right Cessation
- 2007-08-27 US US11/897,028 patent/US8609651B2/en not_active Expired - Fee Related
- 2007-08-27 AU AU2007290589A patent/AU2007290589B2/en not_active Ceased
- 2007-08-27 KR KR1020097006303A patent/KR20090043603A/ko not_active Ceased
- 2007-08-27 WO PCT/US2007/018877 patent/WO2008027357A2/en not_active Ceased
- 2007-08-27 JP JP2009526683A patent/JP2010502614A/ja not_active Ceased
- 2007-08-27 NZ NZ575744A patent/NZ575744A/en not_active IP Right Cessation
- 2007-08-27 UY UY30561A patent/UY30561A1/es unknown
- 2007-08-27 CN CN2007800399467A patent/CN101528261B/zh not_active Expired - Fee Related
- 2007-08-27 US US11/897,002 patent/US8716279B2/en not_active Expired - Fee Related
- 2007-08-27 WO PCT/US2007/018942 patent/WO2008027395A2/en not_active Ceased
- 2007-08-28 AR ARP070103802A patent/AR062556A1/es not_active Application Discontinuation
-
2009
- 2009-02-26 IL IL197275A patent/IL197275A0/en unknown
- 2009-03-23 NO NO20091211A patent/NO20091211L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007290589A1 (en) | 2008-03-06 |
| US8716279B2 (en) | 2014-05-06 |
| EP2068933A2 (en) | 2009-06-17 |
| KR20090043603A (ko) | 2009-05-06 |
| AU2007290589B2 (en) | 2012-04-05 |
| CA2662197A1 (en) | 2008-03-06 |
| AR062556A1 (es) | 2008-11-19 |
| CN101528261A (zh) | 2009-09-09 |
| WO2008027395A2 (en) | 2008-03-06 |
| BRPI0714907A2 (pt) | 2014-08-19 |
| MX2009002310A (es) | 2009-09-21 |
| IL197275A0 (en) | 2009-12-24 |
| US20080070904A1 (en) | 2008-03-20 |
| WO2008027395A3 (en) | 2008-04-17 |
| NO20091211L (no) | 2009-05-27 |
| JP2010502612A (ja) | 2010-01-28 |
| WO2008027357A9 (en) | 2009-04-30 |
| TW200824693A (en) | 2008-06-16 |
| CN101528261B (zh) | 2012-07-18 |
| JP2010502614A (ja) | 2010-01-28 |
| UY30561A1 (es) | 2008-03-31 |
| WO2008027357A2 (en) | 2008-03-06 |
| NZ595388A (en) | 2011-12-22 |
| WO2008027357A3 (en) | 2008-04-17 |
| NZ575744A (en) | 2011-10-28 |
| US8609651B2 (en) | 2013-12-17 |
| US20080076761A1 (en) | 2008-03-27 |
| EP2056877A2 (en) | 2009-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081361A1 (es) | Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas | |
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| BR112015019657A8 (pt) | composições tópicas, kit e método para aumentar a liberação de óxido nítrico a partir de um gel tópico anidro contendo uma macromolécula modificada de diazeniodiolato | |
| BRPI0714399B8 (pt) | composição farmacêutica líquida oral | |
| BR112015008186A2 (pt) | formulação de um anticorpo estável e de baixa viscosidade | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| BR112014029115A8 (pt) | Composto, composição farmacêutica, e, uso de um composto ou composição | |
| BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| CY1117941T1 (el) | Υψηλης συγκεντρωσης φapμαkeytika σκευασματα που περιλαμβανουν το αντισωμα κatα cd20 | |
| ECSP109917A (es) | Nuevos derivados de ácido azabifenilaminobenzoico | |
| AR064826A1 (es) | Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa | |
| AR038575A1 (es) | Formulacion oftalmica con nueva composicion de goma | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| PE20070643A1 (es) | Composiciones farmaceuticas que comprenden buprenorfina | |
| AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
| MX373040B (es) | Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador. | |
| MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| MX2014008283A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. | |
| AR091039A1 (es) | Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento | |
| ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
| BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| BR112015005347A2 (pt) | composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |